DDInter1259 DDInter1762
Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably develop resistance to these agents over time.[A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow for both oral and intravenous administration.[A229853, A229888, A229923, L32033] Following initial hydrolysis, further reactions liberate a highly reactive methyl diazonium cation capable of methylating various residues on adenosine and guanine bases leading to DNA lesions and eventual apoptosis.[A229853, A229923] Temozomolide as an adjunct to radiotherapy followed by maintenance dosing remains the standard of care for both Glioblastoma and refractory anaplastic astrocytoma. Temozolomide was granted FDA approval on August 11, 1999, as an oral capsule and subsequently on February 27, 2009, as an intravenous injection. It is currently marketed under the trademark TEMODAR® by Merck.
Nalidixic acid {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Temozolomide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Temozolomide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Temozolomide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Lomefloxacin
Lomefloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Temozolomide
Nalidixic acid {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Temozolomide
Nalidixic acid {u} (Compound) causes {v} (Side Effect) Visual impairment
Visual impairment {u} (Side Effect) is caused by {v} (Compound) Valproic acid
Valproic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Temozolomide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) downregulates {v} (Gene) DLD
DLD {u} (Gene) is downregulated by {v} (Compound) Temozolomide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temozolomide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Rosoxacin
Rosoxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Temozolomide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Lomefloxacin
Lomefloxacin {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Temozolomide
Nalidixic acid (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Temozolomide (Compound)
Nalidixic acid (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Temozolomide
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Temozolomide
Nalidixic acid (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Temozolomide
Nalidixic acid (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Sparfloxacin (Compound) and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Temozolomide
Nalidixic acid (Compound) causes Visual impairment (Side Effect) and Visual impairment (Side Effect) is caused by Valproic acid (Compound) and Valproic acid may cause a minor interaction that can limit clinical effects when taken with Temozolomide
Nalidixic acid (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Temozolomide (Compound)
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temozolomide (Compound)
Nalidixic acid (Compound) resembles Rosoxacin (Compound) and Rosoxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Temozolomide
Nalidixic acid (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Temozolomide (Compound)